61. Autoimmune hemolytic anemia Clinical trials / Disease details

Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04398459 (ClinicalTrials.gov)	May 1, 2020	18/5/2020	The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia	A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic	Refractory/Relapsed Autoimmune Hemolytic Anemia	Drug: Ibrutinib	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	6 Years	70 Years	All	18	Phase 2	China
2	NCT03827603 (ClinicalTrials.gov)	February 21, 2017	24/1/2019	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia	Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach	AIHA - Warm Autoimmune Hemolytic Anemia	Drug: Ibrutinib	Eugene Nikitin	NULL	Active, not recruiting	18 Years	N/A	All	50	Phase 2	Russian Federation